Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.3K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

4.0K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.0K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.2K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.1K
The pathophysiology of pneumonia involves the following steps:
4.1K
Atypical Pneumonia01:14

Atypical Pneumonia

38
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
38

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gloniopsis spp. causing subcutaneous phaeohyphomycosis: Clinical spectrum, phenotypic, and molecular characterization, antifungal susceptibility and literature review.

Medical mycology·2026
Same author

Contextualizing On-Therapy Resistance Development With Novel Antibiotics: Interplay Between Timing of Therapy Initiation and Critical Illness-Linked Pharmacokinetic/Pharmacodynamic Unpredictability.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma-Experience from Asian Countries.

Clinical lymphoma, myeloma & leukemia·2025
Same author

Role of Pneumococcal Vaccination as a Preventative Measure for At-risk and High-risk Adults: An Indian Narrative.

The Journal of the Association of Physicians of India..·2025
Same author

Real-World Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis.

Cureus·2024
Same author

Indian consensus on the managemeNt of carbapenem-resistant enterobacterales infection in critically ill patients II (ICONIC II).

Expert review of anti-infective therapy·2024

Related Experiment Video

Updated: Mar 30, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K

Pneumococcal Vaccines--a Real World Perspective

Subramanian Swaminathan, G Balajee

    The Journal of the Association of Physicians of India
    |November 14, 2015
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Experimental Human Pneumococcal Carriage
    07:47

    Experimental Human Pneumococcal Carriage

    Published on: February 15, 2013

    16.4K
    Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
    08:47

    Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

    Published on: April 5, 2019

    13.4K

    Related Experiment Videos

    Last Updated: Mar 30, 2026

    Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
    11:32

    Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

    Published on: February 23, 2014

    15.7K
    Experimental Human Pneumococcal Carriage
    07:47

    Experimental Human Pneumococcal Carriage

    Published on: February 15, 2013

    16.4K
    Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
    08:47

    Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

    Published on: April 5, 2019

    13.4K